Journal: Frontiers in Immunology

Article Title: Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents

doi: 10.3389/fimmu.2026.1722115

Figure Lengend Snippet: The interaction between CD4+/CD8+ T cells and antigen-presenting cells (APCs) or tumor cells is regulated by various immune checkpoints, such as the activating checkpoint CD226-CD155, and inhibitory checkpoints including TIGIT-CD155, Tim-3-Galectin-9, and PD1-PDL1. Activation of theseinhibitory checkpoints results in T cell exhaustion and/or functional impairment. Hyperthermia treatment has been shown to upregulate the expressionof TIGIT, Tim-3, and PD1 molecules on T cells, thereby enhancing their responsiveness to immune checkpoint blockade with monoclonal antibodies.

Article Snippet: The inhibitory checkpoints, including PD-1/PD-L1, CTLA-4/CD80/CD86, TIGIT/CD155, Tim-3/Galectin-9, CD47/SIRPα, LAG3/MHC, negatively regulate the activity of immune cells to avoid excessive response such as “cytokine storm”.

Techniques: Activation Assay, Functional Assay, Bioprocessing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns

doi: 10.1007/s00262-026-04343-w

Figure Lengend Snippet: Co-expression of DNAM-1, TACTILE, and TIGIT is correlated with NK cell infiltration in PDAC tumors. A Pie charts illustrating the proportion of T cell subsets expressing DNAM-1, TACTILE, and/or TIGIT. For each subset, pie charts represent cells from peripheral blood (upper row) and tissue (lower row). Pie segments and arcs are color-coded to indicate the expression categories: DNAM-1 + (dark blue arcs), TACTILE + (dark green arcs), TIGIT + (light green arcs), and combinations thereof as defined in the legend below. B Heatmap depicting the absolute difference per T cell subset expressing DNAM-1, TACTILE, and/or TIGIT. The color bar represents the absolute difference in percentage, with decrease (blue) and increase (red) in the tumor. Statistical significance was determined using a linear mixed-effects model. Benjamini-Hochberg correction was applied to adjust p -values. Adjusted p -values < 0.05 were considered significant and depicted in bold with an *. C Pie charts illustrate the proportion of NK cell subsets expressing DNAM-1, TACTILE, and/or TIGIT. The same color legend was used as in A. D Heatmap depicting the absolute difference per NK cell subset expressing DNAM-1, TACTILE, and/or TIGIT. The color bar represents the absolute difference in percentage, with decrease (blue) and increase (red) in the tumor. Statistical significance was determined using a linear mixed-effects model. Benjamini–Hochberg correction was applied to adjust p -values. Adjusted p -values < 0.05 were considered significant and depicted in bold with an *. E Correlation analysis depicting association between the expression of DNAM-1 and NK cell infiltration in PDAC tissue samples. The left panel shows the correlation between the proportion of DNAM-1 + NK cells expressed by the frequency of CD45 + cells (FOCD45). The right panel shows the correlation between geometric mean of DNAM-1 on NK cells. Data points represent individual samples, with the red line indicating the best-fit linear regression and the shaded area representing the confidence interval. Spearman correlation coefficients ( R ) and p -values are depicted. F Correlation analysis depicting association between the gene expression of DNAM-1 and CD155 (left panel) or CD112 (right panel) obtained from TCGA data from PDAC patients. Data points represent individual samples, with the red line indicating the best-fit linear regression and the shaded area representing the confidence interval. Spearman correlation coefficients ( R ) and p -values are depicted

Article Snippet: Other slides were manually stained with antibodies targeting CD155 (Cell Signaling Technology Cat# 81254, RRID:AB_2799970), CD112 (Sigma-Aldrich Cat# HPA012759, RRID:AB_1846227), CD111 (Santa Cruz Biotechnology Cat# sc-21722, RRID:AB_626865), and CD113 (Sigma-Aldrich Cat# SAB1402559, RRID:AB_10638278).

Techniques: Expressing, Gene Expression

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Protein-level profiling of TIGIT axis components in human PDAC reveals immune–suppressive expression patterns

doi: 10.1007/s00262-026-04343-w

Figure Lengend Snippet: High CD155 and CD112 co-expression among nectin family ligands suggests immune evasion via the TIGIT axis in PDAC A Representative histological images of tumor tissue stained with hematoxylin and eosin (HE) and immunohistochemistry staining for CD155, CD112, and CD111. B Dot plots quantifying the percentage of positive tumor cell scores (%) for CD155, CD112, and CD111. Each dot represents the percentage of positive tumor cells in individual samples, with horizontal lines indicating the mean value Shapiro–Wilk test was used to assess normality, and Friedman test was used to determine statistical significance between groups, p < 0.05 was considered significant. C Bar plot showing the mean positive tumor cell scores (%) for CD155, CD112, and CD111 across different tumor stages. Each dot represents an individual sample. D Correlation plot illustrating the correlation between CD112 and CD155 ligand expression determined by immune histochemistry. Each data point represents an individual sample, with the red line indicating the best-fit linear regression and the shaded area representing the confidence interval. Spearman correlation coefficients ( R ) and p -values are depicted. E Heatmap bubble plot displaying the correlation between ligand expression levels. The color intensity represents the Spearman correlation coefficient, while bubble size indicates the statistical significance, as shown in the color legend

Article Snippet: Other slides were manually stained with antibodies targeting CD155 (Cell Signaling Technology Cat# 81254, RRID:AB_2799970), CD112 (Sigma-Aldrich Cat# HPA012759, RRID:AB_1846227), CD111 (Santa Cruz Biotechnology Cat# sc-21722, RRID:AB_626865), and CD113 (Sigma-Aldrich Cat# SAB1402559, RRID:AB_10638278).

Techniques: Expressing, Staining, Immunohistochemistry

Journal: bioRxiv

Article Title: Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I

doi: 10.64898/2026.03.03.708729

Figure Lengend Snippet: (A) Display of ULBP1 and CD155 on CombiCells detected by mAbs and NKG2D-Fc, and DNAM-1-Fc, respectively. (B&C) KIR2DL1+ and KIR2DL1-NK-cell degranulation (CD107a upregulation) in response to ULBP1, CD155, and HLA-C*05:01 displayed on CombiCells. (C) Three types of HLA-C*05:01 were tested, all containing P2 (IIDKSGSTV); wild-type, open and dipeptide exchanged. Data from three independent experiments with NK cells from separate donors are shown.

Article Snippet: Plasmids encoding the ectodomains of ULBP1 (pD649-HAsp-ULBP1-Fc(DAPA)-AviTag-6xHis) and CD155 (pMP71-hCD155) were obtained from Addgene. pMP71-hCD155 was a gift from Sébastien Walchli (Addgene plasmid # 118630; http://n2t.net/addgene:118630 ; RRID:Addgene_118630) [ ]. pD649-HAsp-ULBP1-Fc(DAPA)-AviTag-6xHis was a gift from Chris Garcia (Addgene plasmid # 156597; http://n2t.net/addgene:156597 ; RRID:Addgene_156597) [ ].

Techniques: